

Howard E Gendelman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6142967/publications.pdf>

Version: 2024-02-01

410
papers

26,175
citations

4641

85
h-index

10708

138
g-index

429
all docs

429
docs citations

429
times ranked

24415
citing authors

#	ARTICLE	IF	CITATIONS
1	Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. <i>International Journal of Infectious Diseases</i> , 2022, 114, 45-50.	1.5	11
2	Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils of CRISPR Therapy. <i>Methods in Molecular Biology</i> , 2022, 2407, 429-445.	0.4	3
3	Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. <i>AIDS Reviews</i> , 2022, 24, .	0.5	21
4	Prodrug Therapies for Infectious and Neurodegenerative Diseases. <i>Pharmaceutics</i> , 2022, 14, 518.	2.0	3
5	Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1232-1244.	1.7	16
6	Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. <i>Future Microbiology</i> , 2022, 17, 887-897.	1.0	6
7	Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation. <i>Nature Communications</i> , 2022, 13, .	5.8	21
8	Interleukin-2 expands neuroprotective regulatory T cells in Parkinson's disease. , 2022, .		3
9	Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	11
10	Development of an extended half-life GM-CSF fusion protein for Parkinson's disease. <i>Journal of Controlled Release</i> , 2022, 348, 951-965.	4.8	10
11	Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons. <i>Brain</i> , 2021, 144, 288-309.	3.7	132
12	Europium sulfide nanoprobe predicts antiretroviral drug delivery into HIV-1 cell and tissue reservoirs. <i>Nanotheranostics</i> , 2021, 5, 417-430.	2.7	0
13	Diagnostics for SARS-CoV-2 infections. <i>Nature Materials</i> , 2021, 20, 593-605.	13.3	533
14	A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention. <i>Journal of Neuroimmune Pharmacology</i> , 2021, 16, 270-288.	2.1	30
15	Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca ²⁺ homeostasis in skeletal muscles. <i>Antiviral Research</i> , 2021, 187, 104975.	1.9	4
16	Nanocarrier vaccines for SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 215-239.	6.6	66
17	Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson's disease. <i>Biomaterials</i> , 2021, 272, 120786.	5.7	26
18	Chemical exchange saturation transfer for detection of antiretroviral drugs in brain tissue. <i>Aids</i> , 2021, 35, 1733-1741.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease. <i>EBioMedicine</i> , 2021, 67, 103380.	2.7	23
20	The Immunopathobiology of SARS-CoV-2 Infection. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	9
21	Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir. <i>Nature Communications</i> , 2021, 12, 3453.	5.8	29
22	Humanized Mice for Infectious and Neurodegenerative disorders. <i>Retrovirology</i> , 2021, 18, 13.	0.9	20
23	Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment. <i>Molecular Neurobiology</i> , 2021, 58, 5703-5721.	1.9	12
24	Recovery of Latent HIV-1 from Brain Tissue by Adoptive Cell Transfer in Virally Suppressed Humanized Mice. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 796-805.	2.1	7
25	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles. <i>Nature Communications</i> , 2021, 12, 5458.	5.8	26
26	Pharmacotherapeutics of SARS-CoV-2 Infections. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 12-37.	2.1	4
27	Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions. <i>Frontiers in Immunology</i> , 2021, 12, 741502.	2.2	28
28	CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination. <i>EBioMedicine</i> , 2021, 73, 103678.	2.7	23
29	CD4+ effector T cells accelerate Alzheimer's disease in mice. <i>Journal of Neuroinflammation</i> , 2021, 18, 272.	3.1	48
30	The COVID-19 Pandemic: Reflections of Science, Person, and Challenge in Academic Research Settings. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 706-717.	2.1	1
31	A Link Between Methylglyoxal and Heart Failure During HIV-1 Infection. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 792180.	1.1	3
32	CD4+ T cell effector activities accelerate Alzheimer's disease pathologies.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e052738.	0.4	0
33	Synthesis and Characterization of Long-Acting Darunavir Prodrugs. <i>Molecular Pharmaceutics</i> , 2020, 17, 155-166.	2.3	11
34	Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. <i>Theranostics</i> , 2020, 10, 630-656.	4.6	27
35	Predictive biomarkers for cognitive decline during progressive HIV infection. <i>EBioMedicine</i> , 2020, 51, 102538.	2.7	4
36	Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking. <i>Biomaterials</i> , 2020, 231, 119669.	5.7	16

#	ARTICLE	IF	CITATIONS
37	The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 359-386.	2.1	391
38	Elucidating the pathogenic mechanisms of AD brain-derived, tau-containing extracellular vesicles: Highly transmissible and preferential propagation to GABAergic neurons. <i>Alzheimer's and Dementia</i> , 2020, 16, e037316.	0.4	1
39	HIV-1-Associated Left Ventricular Cardiac Dysfunction in Humanized Mice. <i>Scientific Reports</i> , 2020, 10, 9746.	1.6	5
40	Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. <i>Molecular Neurodegeneration</i> , 2020, 15, 32.	4.4	57
41	Amplification of Replication Competent HIV-1 by Adoptive Transfer of Human Cells From Infected Humanized Mice. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 38.	1.8	7
42	Neuroprotective Activities of Long-Acting Granulocyte-Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice. <i>Neurotherapeutics</i> , 2020, 17, 1861-1877.	2.1	17
43	Pathways towards human immunodeficiency virus elimination. <i>EBioMedicine</i> , 2020, 53, 102667.	2.7	12
44	Immunotherapy for Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 137, 104760.	2.1	57
45	A year-long extended release nanoformulated cabotegravir prodrug. <i>Nature Materials</i> , 2020, 19, 910-920.	13.3	66
46	Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues. <i>Alzheimer's and Dementia</i> , 2020, 16, 896-907.	0.4	105
47	A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 28, 102185.	1.7	12
48	SARS-CoV-2 Infection Leads to Neurological Dysfunction. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 167-173.	2.1	78
49	JNIP Impact Factor Rise Is a Final Tribute to the Years of Impactful Service Made by our Managing Editor. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 341-342.	2.1	0
50	Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases. , 2020, , 335-370.		0
51	Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress. <i>Molecular Neurobiology</i> , 2019, 56, 2896-2907.	1.9	18
52	Synthesis of a long acting nanoformulated emtricitabine ProTide. <i>Biomaterials</i> , 2019, 222, 119441.	5.7	15
53	Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. <i>Nature Communications</i> , 2019, 10, 2753.	5.8	222
54	A long acting nanoformulated lamivudine ProTide. <i>Biomaterials</i> , 2019, 223, 119476.	5.7	24

#	ARTICLE	IF	CITATIONS
55	Creation of a long-acting rilpivirine prodrug nanoformulation. <i>Journal of Controlled Release</i> , 2019, 311-312, 201-211.	4.8	22
56	A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 421.	1.8	32
57	<p>Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 6231-6247.	3.3	16
58	Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases. <i>Drug Discovery Today</i> , 2019, 24, 873-882.	3.2	51
59	Human Interleukin-34 facilitates microglia-like cell differentiation and persistent HIV-1 infection in humanized mice. <i>Molecular Neurodegeneration</i> , 2019, 14, 12.	4.4	53
60	In Appreciation for a Job Well Done!. <i>Journal of NeuroImmune Pharmacology</i> , 2019, 14, 1-1.	2.1	1
61	Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice. <i>Frontiers in Immunology</i> , 2019, 10, 340.	2.2	20
62	The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture. <i>Trends in Microbiology</i> , 2019, 27, 593-606.	3.5	29
63	Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages. <i>Journal of NeuroImmune Pharmacology</i> , 2019, 14, 44-51.	2.1	6
64	Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques. <i>Aids</i> , 2019, 33, 585-588.	1.0	8
65	J-109's Sequential administration of LASER ART and CRISPR-Cas9 can facilitate HIV-1 elimination in humanized mice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 55-55.	0.9	1
66	Moving toward Tuberculosis Elimination. <i>Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 564-571.	2.5	20
67	Neurotheranostics as personalized medicines. <i>Advanced Drug Delivery Reviews</i> , 2019, 148, 252-289.	6.6	63
68	HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication. <i>Journal of NeuroImmune Pharmacology</i> , 2019, 14, 52-67.	2.1	31
69	Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 272-280.	1.3	9
70	Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. <i>Journal of NeuroVirology</i> , 2018, 24, 398-410.	1.0	11
71	Design of mannosylated oral amphotericin B nanoformulation: efficacy and safety in visceral leishmaniasis. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 521-531.	1.9	28
72	Creation of a long-acting nanoformulated dolutegravir. <i>Nature Communications</i> , 2018, 9, 443.	5.8	101

#	ARTICLE	IF	CITATIONS
73	Broad-spectrum antivirals. <i>Nature Materials</i> , 2018, 17, 114-116.	13.3	7
74	Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 153, 248-259.	1.4	13
75	Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. <i>Nanomedicine</i> , 2018, 13, 871-885.	1.7	21
76	Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice. <i>Journal of Neuroimmunology</i> , 2018, 319, 80-92.	1.1	53
77	Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. <i>Biomaterials</i> , 2018, 151, 53-65.	5.7	77
78	Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	30
79	P1025: EXOSOMES CONTAINING SPECIFIC TAU OLIGOMER FORMATIONS ACCELERATE PATHOLOGICAL TAU PHOSPHORYLATION IN C57BL/6 MICE. <i>Alzheimer's and Dementia</i> , 2018, 14, P275.	0.4	1
80	P-A9 Transformation of Darunavir into a long acting nanoformulated prodrug. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 55-55.	0.9	0
81	P-A8 Establishing tissue reservoirs for the human immunodeficiency virus in humanized mice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 55-55.	0.9	0
82	O102: CHARACTERIZATION OF HUMAN ALZHEIMER'S DISEASE BRAIN-DERIVED EXOSOMES. <i>Alzheimer's and Dementia</i> , 2018, 14, P608.	0.4	1
83	Biodegradable polyanhydride-based nanomedicines for blood to brain drug delivery. <i>Journal of Biomedical Materials Research - Part A</i> , 2018, 106, 2881-2890.	2.1	19
84	Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. <i>Biomaterials</i> , 2018, 185, 174-193.	5.7	27
85	Neuropathogenesis of human immunodeficiency virus infection. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 152, 21-40.	1.0	31
86	EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment. <i>PLoS Pathogens</i> , 2018, 14, e1007061.	2.1	51
87	Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. <i>Theranostics</i> , 2018, 8, 256-276.	4.6	40
88	ProTide generated long-acting abacavir nanoformulations. <i>Chemical Communications</i> , 2018, 54, 8371-8374.	2.2	17
89	D-110 Synergism between CRISPR/Cas9 and LASER ART leads to elimination of HIV-1 with no rebound in Humanized Mice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 42-42.	0.9	0
90	URMC-099 facilitates amyloid- β clearance in a murine model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2018, 15, 137.	3.1	36

#	ARTICLE	IF	CITATIONS
91	Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2018, 13, 26.	4.4	39
92	Modulating cellular autophagy for controlled antiretroviral drug release. <i>Nanomedicine</i> , 2018, 13, 2139-2154.	1.7	9
93	Long-Acting Nanoformulated Antiretroviral Therapy. , 2018, , 1211-1220.		0
94	Control of Neuroinflammation for Therapeutic Gain. , 2017, , 971-978.		0
95	Long-acting slow effective release antiretroviral therapy. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1281-1291.	2.4	53
96	The cortical signature of symptom laterality in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2017, 14, 433-440.	1.4	51
97	Creation of a Long-Acting Nanoformulated 2'-3'-Dideoxy-3'-Thiacytidine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, e75-e83.	0.9	41
98	P-D5 Synthesis and characterization of core-shell silica cobalt ferrite nanoparticles as a first step towards developing ultrasensitive MRI probes for long-acting antiretroviral drug biodistribution testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 91.	0.9	1
99	Cathepsin B Improves β -Amyloidosis and Learning and Memory in Models of Alzheimer's Disease. <i>Journal of Neuroimmune Pharmacology</i> , 2017, 12, 340-352.	2.1	51
100	A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. <i>Retrovirology</i> , 2017, 14, 17.	0.9	94
101	Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging. <i>Acta Biomaterialia</i> , 2017, 49, 507-520.	4.1	28
102	Overview of Mononuclear Phagocytes. , 2017, , 141-153.		0
103	Macrophages, Microglia and Dendritic Cell Function. , 2017, , 155-166.		0
104	Immunotherapies for Movement Disorders: Parkinson's Disease and Amyotrophic Lateral Sclerosis. , 2017, , 767-797.		1
105	T cells and Parkinson's disease. <i>Lancet Neurology</i> , The, 2017, 16, 769-771.	4.9	22
106	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. <i>Npj Parkinson's Disease</i> , 2017, 3, 10.	2.5	98
107	Proteomic analysis of mesenchymal to Schwann cell transdifferentiation. <i>Journal of Proteomics</i> , 2017, 165, 93-101.	1.2	21
108	Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis. <i>Nanomedicine</i> , 2017, 12, 99-115.	1.7	76

#	ARTICLE	IF	CITATIONS
109	Thank You!. <i>Journal of NeuroImmune Pharmacology</i> , 2017, 12, 565-565.	2.1	0
110	Systemic HIV-1 infection produces a unique glial footprint in humanized mouse brains. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 1489-1502.	1.2	15
111	Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. <i>Journal of Clinical Investigation</i> , 2017, 127, 857-873.	3.9	44
112	MEMRI is a biomarker defining nicotine-specific neuronal responses in subregions of the rodent brain. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 601-610.	0.0	7
113	Quiet connections: Reduced fronto-temporal connectivity in nondemented Parkinson's Disease during working memory encoding. <i>Human Brain Mapping</i> , 2016, 37, 3224-3235.	1.9	41
114	Neuropharmacologic Approaches to Restore the Brain's Microenvironment. <i>Journal of NeuroImmune Pharmacology</i> , 2016, 11, 484-494.	2.1	10
115	HIV-1 cellular and tissue replication patterns in infected humanized mice. <i>Scientific Reports</i> , 2016, 6, 23513.	1.6	59
116	The mixed-lineage kinase 3 inhibitor URM-099 facilitates microglial amyloid- β degradation. <i>Journal of Neuroinflammation</i> , 2016, 13, 184.	3.1	22
117	Development and characterization of a long-acting nanoformulated abacavir prodrug. <i>Nanomedicine</i> , 2016, 11, 1913-1927.	1.7	41
118	Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease. <i>Neurotherapeutics</i> , 2016, 13, 635-646.	2.1	24
119	Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2R β c null Mouse Brain Atlas. <i>Journal of NeuroImmune Pharmacology</i> , 2016, 11, 133-141.	2.1	2
120	The mixed lineage kinase-3 inhibitor URM-099 improves therapeutic outcomes for long-acting antiretroviral therapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 109-122.	1.7	27
121	Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. <i>Current Opinion in Pharmacology</i> , 2016, 26, 87-95.	1.7	46
122	Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. <i>Molecular Neurobiology</i> , 2016, 53, 3286-3297.	1.9	14
123	Long-Acting Nanoformulated Antiretroviral Therapy. , 2016, , 1-10.		1
124	Metabolic drift in the aging brain. <i>Aging</i> , 2016, 8, 1000-1020.	1.4	89
125	Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. <i>PLoS ONE</i> , 2015, 10, e0145966.	1.1	13
126	Magnetic resonance imaging of folic acid-coated magnetite nanoparticles reflects tissue biodistribution of long-acting antiretroviral therapy. <i>International Journal of Nanomedicine</i> , 2015, 10, 3779.	3.3	17

#	ARTICLE	IF	CITATIONS
127	A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders. <i>Journal of NeuroImmune Pharmacology</i> , 2015, 10, 645-650.	2.1	36
128	Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice. <i>Journal of Neuroscience</i> , 2015, 35, 16463-16478.	1.7	68
129	Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 715-729.	1.7	46
130	Comprehensive bioimaging with fluorinated nanoparticles using breathable liquids. <i>Nature Communications</i> , 2015, 6, 5998.	5.8	50
131	Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. <i>Biomaterials</i> , 2015, 41, 141-150.	5.7	58
132	Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages. <i>Retrovirology</i> , 2015, 12, 5.	0.9	33
133	Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice. <i>Antiviral Research</i> , 2015, 120, 85-88.	1.9	23
134	Potential of N-acetylated-para-aminosalicylic acid to accelerate manganese enhancement decline for long-term MEMRI in rodent brain. <i>Journal of Neuroscience Methods</i> , 2015, 251, 92-98.	1.3	2
135	Granulocyte-Macrophage Colony Stimulating Factor Exerts Protective and Immunomodulatory Effects in Cortical Trauma. <i>Journal of Neuroimmunology</i> , 2015, 278, 162-173.	1.1	30
136	Presenilin-1 familial Alzheimer's disease mutation alters hippocampal neurogenesis and memory function in CCL2 null mice. <i>Brain, Behavior, and Immunity</i> , 2015, 49, 311-321.	2.0	15
137	Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 751-767.	1.7	98
138	AAV2/1 CD74 Gene Transfer Reduces β -amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease. <i>Molecular Therapy</i> , 2015, 23, 1712-1721.	3.7	34
139	Influence of age, irradiation and humanization on NSG mouse phenotypes. <i>Biology Open</i> , 2015, 4, 1243-1252.	0.6	24
140	Nano-enabled delivery of diverse payloads across complex biological barriers. <i>Journal of Controlled Release</i> , 2015, 219, 548-559.	4.8	54
141	An interactive cluster heat map to visualize and explore multidimensional metabolomic data. <i>Metabolomics</i> , 2015, 11, 1029-1034.	1.4	39
142	Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins. <i>Nanomedicine</i> , 2014, 9, 1403-1422.	1.7	78
143	Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. <i>Molecular Neurodegeneration</i> , 2014, 9, 58.	4.4	52
144	Small magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution. <i>Nanomedicine</i> , 2014, 9, 1341-1352.	1.7	11

#	ARTICLE	IF	CITATIONS
145	Pharmacokinetics, Biodistribution, and Toxicity of Folic Acid-Coated Antiretroviral Nanoformulations. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7510-7519.	1.4	21
146	Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. <i>Translational Neurodegeneration</i> , 2014, 3, 25.	3.6	65
147	Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 585-590.	1.5	15
148	Hypersynchrony despite pathologically reduced beta oscillations in patients with Parkinson's disease: a pharmaco-magnetoencephalography study. <i>Journal of Neurophysiology</i> , 2014, 112, 1739-1747.	0.9	72
149	Fourth Annual Conference of the American Society for Nanomedicine. <i>Journal of Neuroimmune Pharmacology</i> , 2014, 9, 1-38.	2.1	2
150	Bench-to-bedside translation of magnetic nanoparticles. <i>Nanomedicine</i> , 2014, 9, 501-516.	1.7	58
151	The promise of nanoneuromedicine. <i>Nanomedicine</i> , 2014, 9, 171-176.	1.7	12
152	Brain Region Mapping Using Global Metabolomics. <i>Chemistry and Biology</i> , 2014, 21, 1575-1584.	6.2	65
153	Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes. <i>FASEB Journal</i> , 2014, 28, 5071-5082.	0.2	39
154	Endosomal Trafficking of Nanoformulated Antiretroviral Therapy Facilitates Drug Particle Carriage and HIV Clearance. <i>Journal of Virology</i> , 2014, 88, 9504-9513.	1.5	48
155	Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues. <i>Nanomedicine</i> , 2014, 9, 469-485.	1.7	47
156	Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies. <i>Current Medicinal Chemistry</i> , 2014, 21, 4186-4198.	1.2	75
157	Bench-to-bedside translation of magnetic nanoparticles. <i>Nanomedicine</i> , 2014, 9, 501-16.	1.7	36
158	Neuronanomedicine. <i>Springer Protocols</i> , 2014, , 223-231.	0.1	0
159	Centrifugal Elutriation for Studies of Neuroimmunity. <i>Springer Protocols</i> , 2014, , 165-175.	0.1	1
160	Cell-Based Drug Delivery for Improving Antiretroviral Therapeutic Outcomes. , 2014, , 529-546.		0
161	Nanomedicines for Nervous System Diseases. , 2014, , 2125-2156.		0
162	Bridge between neuroimmunity and traumatic brain injury. <i>Current Pharmaceutical Design</i> , 2014, 20, 4284-98.	0.9	45

#	ARTICLE	IF	CITATIONS
163	Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. <i>Journal of NeuroVirology</i> , 2013, 19, 254-260.	1.0	14
164	Improved Visualization of Neuronal Injury Following Glial Activation by Manganese Enhanced MRI. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 1027-1036.	2.1	13
165	Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 1224-1238.	2.1	30
166	Enhancement of NMDA Receptor-Mediated Excitatory Postsynaptic Currents by gp120-Treated Macrophages: Implications for HIV-1-Associated Neuropathology. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 921-933.	2.1	13
167	GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. <i>Journal of Neuroimmunology</i> , 2013, 265, 1-10.	1.1	90
168	Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 1263-1273.	1.7	83
169	Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3110-3120.	1.4	70
170	CCL2 affects β -amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 1060-1068.	1.5	67
171	Immunoisolation of Nanoparticles Containing Endocytic Vesicles for Drug Quantitation. <i>Methods in Molecular Biology</i> , 2013, 991, 41-46.	0.4	5
172	Methods for Isolation and Identification of Nanoparticle-Containing Subcellular Compartments. <i>Methods in Molecular Biology</i> , 2013, 991, 47-55.	0.4	6
173	Functional Proteome of Macrophage Carried Nanoformulated Antiretroviral Therapy Demonstrates Enhanced Particle Carrying Capacity. <i>Journal of Proteome Research</i> , 2013, 12, 2282-2294.	1.8	20
174	Lipids and cognition make good bedfellows for neuroAIDS. <i>Neurology</i> , 2013, 81, 1480-1481.	1.5	2
175	Mouse brain fixation to preserve In vivo manganese enhancement for ex vivo manganese-enhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 482-487.	1.9	13
176	Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. <i>Nanomedicine</i> , 2013, 8, 1807-1813.	1.7	85
177	Specific Transfection of Inflamed Brain by Macrophages: A New Therapeutic Strategy for Neurodegenerative Diseases. <i>PLoS ONE</i> , 2013, 8, e61852.	1.1	124
178	Neuroimmune Cross Talk and HIV-Associated Neurocognitive Disorders. , 2013, , 211-248.		0
179	Inflammation and Adaptive Immunity in Parkinson's Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a009381-a009381.	2.9	221
180	Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. <i>Aids</i> , 2012, 26, 2135-2144.	1.0	121

#	ARTICLE	IF	CITATIONS
181	Immunization strategies for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S218-S221.	1.1	26
182	Rodent models for HIV-associated neurocognitive disorders. <i>Trends in Neurosciences</i> , 2012, 35, 197-208.	4.2	66
183	Biochemical and Biologic Characterization of Exosomes and Microvesicles as Facilitators of HIV-1 Infection in Macrophages. <i>Journal of Immunology</i> , 2012, 189, 744-754.	0.4	198
184	A call for transparent reporting to optimize the predictive value of preclinical research. <i>Nature</i> , 2012, 490, 187-191.	13.7	1,055
185	A model of nitric oxide induced α -synuclein misfolding in Parkinson's disease. <i>Neuroscience Letters</i> , 2012, 523, 167-173.	1.0	38
186	Rapid and reliable quantitation of amino acids and myo-inositol in mouse brain by high performance liquid chromatography and tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 893-894, 15-20.	1.2	27
187	Changes in the plasma proteome follows chronic opiate administration in simian immunodeficiency virus infected rhesus macaques. <i>Drug and Alcohol Dependence</i> , 2012, 120, 105-112.	1.6	10
188	Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease. <i>PLoS ONE</i> , 2012, 7, e38113.	1.1	106
189	CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson's Disease. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 927-938.	2.1	255
190	Change in Evolution. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 715-716.	2.1	0
191	Plasma Proteomic Profiling in HIV-1 Infected Methamphetamine Abusers. <i>PLoS ONE</i> , 2012, 7, e31031.	1.1	19
192	Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. <i>International Journal of Nanomedicine</i> , 2012, 7, 2373.	3.3	48
193	Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1 Infected Human Peripheral Blood Lymphocyte-Reconstituted Mice. <i>Journal of Infectious Diseases</i> , 2012, 206, 1577-1588.	1.9	62
194	Can Humanized Mice Reflect the Complex Pathobiology of HIV-Associated Neurocognitive Disorders?. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 352-362.	2.1	27
195	Commentary: Animal Models of NeuroAIDS. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 301-305.	2.1	7
196	Murine Motor and Behavior Functional Evaluations for Acute 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Intoxication. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 279-288.	2.1	26
197	Methamphetamine-Associated Psychosis. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 113-139.	2.1	202
198	Not Just Another Jigsaw Puzzle. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 1-2.	2.1	2

#	ARTICLE	IF	CITATIONS
199	Macrophage Bridging Conduit Trafficking of HIV-1 Through the Endoplasmic Reticulum and Golgi Network. <i>Journal of Proteome Research</i> , 2011, 10, 3225-3238.	1.8	68
200	Pulsed Stable Isotope Labeling of Amino Acids in Cell Culture Uncovers the Dynamic Interactions between HIV-1 and the Monocyte-Derived Macrophage. <i>Journal of Proteome Research</i> , 2011, 10, 2852-2862.	1.8	20
201	Cell Delivery of Therapeutic Nanoparticles. <i>Progress in Molecular Biology and Translational Science</i> , 2011, 104, 563-601.	0.9	101
202	Cell-mediated drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 415-433.	2.4	274
203	Neuroprotective activities of regulatory T cells. <i>Trends in Molecular Medicine</i> , 2011, 17, 687-688.	3.5	41
204	BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. <i>Neuroscience</i> , 2011, 180, 293-304.	1.1	9
205	<i>Fusobacterium necrophorum</i> causing infective endocarditis and liver and splenic abscesses. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2011, 53, 169-172.	0.5	16
206	Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. <i>International Journal of Nanomedicine</i> , 2011, 6, 3393.	3.3	37
207	Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease. <i>Journal of Nanomedicine & Nanotechnology</i> , 2011, 01, .	1.1	58
208	Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. <i>Journal of Controlled Release</i> , 2011, 150, 204-211.	4.8	107
209	Brain ingress of regulatory T cells in a murine model of HIV-1 encephalitis. <i>Journal of Neuroimmunology</i> , 2011, 230, 33-41.	1.1	28
210	Proteomic biosignatures for monocyte macrophage differentiation. <i>Cellular Immunology</i> , 2011, 271, 239-255.	1.4	18
211	Human Immunodeficiency Virus type 1 Endocytic Trafficking Through Macrophage Bridging Conduits Facilitates Spread of Infection. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 658-675.	2.1	75
212	UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 2332-2338.	1.2	33
213	Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice. <i>Journal of Neuroscience</i> , 2011, 31, 3148-3157.	1.7	110
214	Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells. <i>Nanomedicine</i> , 2011, 6, 1215-1230.	1.7	67
215	Macrophage endocytic trafficking of antiretroviral nanoparticles. <i>Nanomedicine</i> , 2011, 6, 975-994.	1.7	62
216	Pathways towards an effective immunotherapy for Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1703-1715.	1.4	29

#	ARTICLE	IF	CITATIONS
217	Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. <i>Nanotoxicology</i> , 2011, 5, 592-605.	1.6	26
218	Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs. <i>Journal of Visualized Experiments</i> , 2010, , .	0.2	17
219	Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. <i>Blood</i> , 2010, 115, 4951-4962.	0.6	115
220	Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring. <i>Journal of Visualized Experiments</i> , 2010, , .	0.2	3
221	Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics. <i>Journal of NeuroImmune Pharmacology</i> , 2010, 5, 592-601.	2.1	97
222	Immunoregulation of a CB2 Receptor Agonist in a Murine Model of NeuroAIDS. <i>Journal of NeuroImmune Pharmacology</i> , 2010, 5, 456-468.	2.1	48
223	Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. <i>Journal of Controlled Release</i> , 2010, 143, 290-301.	4.8	142
224	HIV-1 neuroimmunity in the era of antiretroviral therapy. <i>Neurobiology of Disease</i> , 2010, 37, 542-548.	2.1	78
225	Rebuilding Synaptic Architecture in HIV-1 Associated Neurocognitive Disease: A Therapeutic Strategy Based on Modulation of Mixed Lineage Kinase. <i>Neurotherapeutics</i> , 2010, 7, 392-398.	2.1	11
226	Proteomic analyses of monocytes obtained from Hispanic women with HIV-associated dementia show depressed antioxidants. <i>Proteomics - Clinical Applications</i> , 2010, 4, 706-714.	0.8	22
227	Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2010, 114, 1261-1276.	2.1	36
228	Regulatory T Cells Attenuate Th17 Cell-Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinson's Disease. <i>Journal of Immunology</i> , 2010, 184, 2261-2271.	0.4	346
229	CD8+ Cell Depletion Accelerates HIV-1 Immunopathology in Humanized Mice. <i>Journal of Immunology</i> , 2010, 184, 7082-7091.	0.4	80
230	Neuroprotective Activities of CEP-1347 in Models of NeuroAIDS. <i>Journal of Immunology</i> , 2010, 184, 746-756.	0.4	47
231	Neuroprotective Activities of CD4+CD25+ Regulatory T Cells. <i>NeuroImmune Biology</i> , 2010, 9, 197-210.	0.2	0
232	Plasma Proteomic Analysis of Simian Immunodeficiency Virus Infection of Rhesus Macaques. <i>Journal of Proteome Research</i> , 2010, 9, 4721-4731.	1.8	21
233	CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. <i>FASEB Journal</i> , 2010, 24, 3093-3102.	0.2	187
234	Functional Proteomic Analysis for Regulatory T Cell Surveillance of the HIV-1-Infected Macrophage. <i>Journal of Proteome Research</i> , 2010, 9, 6759-6773.	1.8	29

#	ARTICLE	IF	CITATIONS
235	Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. <i>Nanomedicine</i> , 2010, 5, 379-396.	1.7	154
236	Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. <i>Experimental Neurology</i> , 2010, 222, 1-5.	2.0	25
237	Links between Progressive HIV-1 Infection of Humanized Mice and Viral Neuropathogenesis. <i>American Journal of Pathology</i> , 2010, 177, 2938-2949.	1.9	94
238	CCL2 Accelerates Microglia-Mediated A β Oligomer Formation and Progression of Neurocognitive Dysfunction. <i>PLoS ONE</i> , 2009, 4, e6197.	1.1	100
239	Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS. <i>Journal of Immunology</i> , 2009, 183, 661-669.	0.4	211
240	Neuromodulatory Activities of CD4+CD25+ Regulatory T Cells in a Murine Model of HIV-1-Associated Neurodegeneration. <i>Journal of Immunology</i> , 2009, 182, 3855-3865.	0.4	82
241	Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 2151-2166.	2.5	114
242	AAV1/2-mediated CNS Gene Delivery of Dominant-negative CCL2 Mutant Suppresses Gliosis, β -amyloidosis, and Learning Impairment of APP/PS1 Mice. <i>Molecular Therapy</i> , 2009, 17, 803-809.	3.7	62
243	Registration of in vivo MR to histology of rodent brains using blockface imaging. <i>Proceedings of SPIE</i> , 2009, , .	0.8	5
244	Nitrated β -Synuclein-Induced Alterations in Microglial Immunity Are Regulated by CD4+ T Cell Subsets. <i>Journal of Immunology</i> , 2009, 182, 4137-4149.	0.4	177
245	Simvastatin Inhibits the Activation of p21 ^{ras} and Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2009, 29, 13543-13556.	1.7	156
246	NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. <i>Nanomedicine</i> , 2009, 4, 903-917.	1.7	116
247	CD 4+ T cells in the pathobiology of neurodegenerative disorders. <i>Journal of Neuroimmunology</i> , 2009, 211, 3-15.	1.1	48
248	Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. <i>Journal of Neuroimmunology</i> , 2009, 213, 47-59.	1.1	24
249	HIV-1 transforms the monocyte plasma membrane proteome. <i>Cellular Immunology</i> , 2009, 258, 44-58.	1.4	25
250	Monocyte Chemotactic Protein-1 Regulates Voltage-Gated K ⁺ Channels and Macrophage Transmigration. <i>Journal of NeuroImmune Pharmacology</i> , 2009, 4, 47-59.	2.1	44
251	4-Aminopyridine Improves Spatial Memory in a Murine Model of HIV-1 Encephalitis. <i>Journal of NeuroImmune Pharmacology</i> , 2009, 4, 317-327.	2.1	23
252	Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. <i>Journal of NeuroVirology</i> , 2009, 15, 176-186.	1.0	90

#	ARTICLE	IF	CITATIONS
253	A Coat of Many Colors: Neuroimmune Crosstalk in Human Immunodeficiency Virus Infection. <i>Neuron</i> , 2009, 64, 133-145.	3.8	110
254	NanoART, neuroAIDS and CNS drug delivery. <i>Nanomedicine</i> , 2009, 4, 557-574.	1.7	112
255	Neurodegenerative disorders and nanoformulated drug development. <i>Nanomedicine</i> , 2009, 4, 541-555.	1.7	61
256	Proteomic Studies of Nitrated Alpha-Synuclein Microglia Regulation by CD4+CD25+ T Cells. <i>Journal of Proteome Research</i> , 2009, 8, 3497-3511.	1.8	78
257	Facilitated Monocyte-Macrophage Uptake and Tissue Distribution of Superparamagnetic Iron-Oxide Nanoparticles. <i>PLoS ONE</i> , 2009, 4, e4343.	1.1	116
258	Nitrated Alpha-Synuclein and Microglial Neuroregulatory Activities. <i>Journal of NeuroImmune Pharmacology</i> , 2008, 3, 59-74.	2.1	113
259	Opendra "Bill" Narayan (1936-2007): A Personal Tribute to a Friend, Teacher, and Colleague. <i>Journal of NeuroImmune Pharmacology</i> , 2008, 3, 1-4.	2.1	0
260	The Promise and Perils of CNS Drug Delivery: A Video Debate. <i>Journal of NeuroImmune Pharmacology</i> , 2008, 3, 58-58.	2.1	10
261	Disseminating Research Discovery Through an Interactive Video: a Paradigm Shift for Journal Publication. <i>Journal of NeuroImmune Pharmacology</i> , 2008, 3, 57-57.	2.1	0
262	HIV-1-Infected Astrocytes and the Microglial Proteome. <i>Journal of NeuroImmune Pharmacology</i> , 2008, 3, 173-186.	2.1	44
263	Modulation of innate immunity by copolymer β 1 leads to neuroprotection in murine HIV β 1 encephalitis. <i>Glia</i> , 2008, 56, 223-232.	2.5	18
264	Nitrated alpha β synuclein β activated microglial profiling for Parkinson β ™s disease. <i>Journal of Neurochemistry</i> , 2008, 104, 1504-1525.	2.1	195
265	Ingress of blood-borne macrophages across the blood-brain barrier in murine HIV-1 encephalitis. <i>Journal of Neuroimmunology</i> , 2008, 200, 41-52.	1.1	17
266	Erratum to "CSF proteomic fingerprints for HIV-associated cognitive impairment". <i>Journal of Neuroimmunology</i> , 2008, 205, 161.	1.1	0
267	Nitrated β synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons. <i>PLoS ONE</i> , 2008, 3, e1376.	1.1	311
268	Introducing Neuroimmune Pharmacology. , 2008, , 1-3.		0
269	Macrophages, Microglia, and Dendritic C. , 2008, , 89-104.		1
270	STAT1 signaling modulates HIV-1 β induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. <i>Blood</i> , 2008, 111, 2062-2072.	0.6	130

#	ARTICLE	IF	CITATIONS
271	Proteomic Modeling for HIV-1 Infected Microglia-Astrocyte Crosstalk. PLoS ONE, 2008, 3, e2507.	1.1	46
272	Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice. PLoS ONE, 2008, 3, e2740.	1.1	174
273	The neuropathogenesis of HIV-1 infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 85, 45-67.	1.0	11
274	Copolymer-1 Induces Adaptive Immune Anti-inflammatory Glial and Neuroprotective Responses in a Murine Model of HIV-1 Encephalitis. Journal of Immunology, 2007, 179, 4345-4356.	0.4	36
275	Human Immunodeficiency Virus Type 1 Pathobiology Studied in Humanized BALB/c-Rag2 ^{-/-} Î³c ^{-/-} Mice. Journal of Virology, 2007, 81, 2700-2712.	1.5	130
276	Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 235-242.	2.3	19
277	Cytoskeletal Protein Transformation in HIV-1-Infected Macrophage Giant Cells. Journal of Immunology, 2007, 178, 6404-6415.	0.4	46
278	Selective inhibition of NF-Î²B activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18754-18759.	3.3	391
279	Interferon-Î³ and Tumor Necrosis Factor-Î± Regulate Amyloid-Î² Plaque Deposition and Î²-Secretase Expression in Swedish Mutant APP Transgenic Mice. American Journal of Pathology, 2007, 170, 680-692.	1.9	348
280	Oxidative Stress and the Pathogenesis of Neurodegenerative Disorders. International Review of Neurobiology, 2007, 82, 297-325.	0.9	350
281	Cerebrospinal Fluid Proteomic Profiling of HIV-1-Infected Patients with Cognitive Impairment. Journal of Proteome Research, 2007, 6, 4189-4199.	1.8	95
282	A Macrophage ⁺ Nanozyme Delivery System for Parkinson's Disease. Bioconjugate Chemistry, 2007, 18, 1498-1506.	1.8	177
283	Neuroprotective activities of CD4 ⁺ CD25 ⁺ regulatory T cells in an animal model of Parkinson's disease. Journal of Leukocyte Biology, 2007, 82, 1083-1094.	1.5	323
284	T cell independent mechanism for copolymer ¹ induced neuroprotection. European Journal of Immunology, 2007, 37, 3143-3154.	1.6	62
285	HIV-1 gp120 Compromises Blood-Brain Barrier Integrity and Enhance Monocyte Migration across Blood-Brain Barrier: Implication for Viral Neuropathogenesis. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 123-134.	2.4	202
286	Novel Delivery System Enhances Efficacy of Antiretroviral Therapy in Animal Model for HIV-1 Encephalitis. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1033-1042.	2.4	67
287	Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. Journal of Neurochemistry, 2007, 100, 503-519.	2.1	115
288	Genomic and proteomic microglial profiling: pathways for neuroprotective inflammatory responses following nerve fragment clearance and activation. Journal of Neurochemistry, 2007, 102, 627-645.	2.1	64

#	ARTICLE	IF	CITATIONS
289	Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. <i>Virology</i> , 2007, 358, 148-158.	1.1	90
290	Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. <i>Virology</i> , 2007, 363, 198-209.	1.1	72
291	Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. <i>Neurobiology of Disease</i> , 2007, 26, 146-152.	2.1	44
292	Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2007, 26, 590-596.	2.1	114
293	CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. <i>Journal of Neuroimmunology</i> , 2007, 183, 60-68.	1.1	90
294	HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: New insights into blood-brain barrier dysfunction for HIV-1-associated dementia. <i>Journal of Neuroimmunology</i> , 2007, 185, 37-46.	1.1	63
295	CSF proteomic fingerprints for HIV-associated cognitive impairment. <i>Journal of Neuroimmunology</i> , 2007, 192, 157-170.	1.1	57
296	Biomarkers, Laboratory, and Animal Models for the Design and Development of Adjunctive Therapies for HIV-1 Dementia and other Neuroinflammatory Disorders. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 8-13.	2.1	13
297	Glycogen Synthase Kinase 3 Beta (GSK-3 β) as a Therapeutic Target in NeuroAIDS. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 93-96.	2.1	39
298	The Journal of Neuroimmune Pharmacology Reaches Its Stride. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 129-130.	2.1	0
299	A Functional Transsulfuration Pathway in the Brain Links to Glutathione Homeostasis. <i>Journal of Biological Chemistry</i> , 2006, 281, 35785-35793.	1.6	198
300	Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. <i>Blood</i> , 2006, 108, 2827-2835.	0.6	241
301	Chemokines and Their Receptors and the Neuropathogenesis of HIV-1 Infection. , 2006, , 45-80.		1
302	Debate: "Is Increasing Neuroinflammation Beneficial for Neural Repair?" <i>Journal of NeuroImmune Pharmacology</i> , 2006, 1, 195-211.	2.1	63
303	Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System. <i>Journal of NeuroImmune Pharmacology</i> , 2006, 1, 340-350.	2.1	222
304	Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson's disease. <i>Clinical Neuroscience Research</i> , 2006, 6, 261-281.	0.8	305
305	Neuropathologic and neuroinflammatory activities of HIV-1-infected human astrocytes in murine brain. <i>Glia</i> , 2006, 54, 81-93.	2.5	34
306	HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1 β . <i>Glia</i> , 2006, 54, 619-629.	2.5	92

#	ARTICLE	IF	CITATIONS
307	Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis. <i>Current HIV Research</i> , 2006, 4, 279-291.	0.2	34
308	Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1165-1174.	1.5	64
309	Monocyte Differentiation, Activation, and Mycobacterial Killing Are Linked to Transsulfuration-dependent Redox Metabolism. <i>Journal of Biological Chemistry</i> , 2006, 281, 38712-38720.	1.6	31
310	Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. <i>Blood</i> , 2005, 106, 2382-2390.	0.6	144
311	Infections of the nervous system. <i>Lancet Neurology</i> , The, 2005, 4, 12-13.	4.9	25
312	Development of a rapid autopsy program for studies of brain immunity. <i>Journal of Neuroimmunology</i> , 2005, 163, 135-144.	1.1	19
313	Neuroinflammatory responses from microglia recovered from HIV-1-infected and seronegative subjects. <i>Journal of Neuroimmunology</i> , 2005, 163, 145-156.	1.1	26
314	Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations. <i>Glia</i> , 2005, 51, 161-172.	2.5	29
315	Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis. <i>Glia</i> , 2005, 52, 344-353.	2.5	54
316	Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. <i>Neurotoxicity Research</i> , 2005, 8, 25-50.	1.3	66
317	Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection against HIV-1 Challenge. <i>Journal of Virology</i> , 2005, 79, 2124-2132.	1.5	44
318	Neuroprotective Mechanisms of Lithium in Murine Human Immunodeficiency Virus-1 Encephalitis. <i>Journal of Neuroscience</i> , 2005, 25, 8375-8385.	1.7	72
319	Quantitative 1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2005, 25, 1691-1700.	1.7	76
320	Overexpression of Monocyte Chemotactic Protein-1/CCL2 in β 2-Amyloid Precursor Protein Transgenic Mice Show Accelerated Diffuse β 2-Amyloid Deposition. <i>American Journal of Pathology</i> , 2005, 166, 1475-1485.	1.9	130
321	Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring. <i>Current HIV Research</i> , 2004, 2, 61-78.	0.2	36
322	Neuroregulatory Events Follow Adaptive Immune-Mediated Elimination of HIV-1-Infected Macrophages: Studies in a Murine Model of Viral Encephalitis. <i>Journal of Immunology</i> , 2004, 172, 7610-7617.	0.4	51
323	Memantine Protects Hippocampal Neuronal Function in Murine Human Immunodeficiency Virus Type 1 Encephalitis. <i>Journal of Neuroscience</i> , 2004, 24, 7194-7198.	1.7	71
324	Molecular Characterization of a Putative Antiretroviral Transcriptional Factor, OTK18. <i>Journal of Immunology</i> , 2004, 172, 381-391.	0.4	31

#	ARTICLE	IF	CITATIONS
325	Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9435-9440.	3.3	299
326	Proteomic fingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	1.0	21
327	Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. Journal of NeuroVirology, 2004, 10, 82-90.	1.0	3
328	Proteomic fingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	1.0	19
329	Proteomic fingerprinting of HIV-1-infected human monocyte-derived macrophages: a preliminary report. Journal of Neuroimmunology, 2004, 147, 35-42.	1.1	19
330	TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia. Journal of Neuroimmunology, 2004, 148, 127-139.	1.1	55
331	OTK18 expression in brain mononuclear phagocytes parallels the severity of HIV-1 encephalitis. Journal of Neuroimmunology, 2004, 150, 186-198.	1.1	19
332	Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease. Journal of Neuroimmunology, 2004, 157, 11-16.	1.1	33
333	Proteomic fingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	1.0	17
334	Neuroprotective strategies for HIV-1 associated dementia. Neurotoxicity Research, 2004, 6, 503-521.	1.3	29
335	The Neuropathogenesis of HIV-1 Infection. , 2004, , 95-115.		8
336	Neural Immunity and Human Immunodeficiency Virus-1-Associated Dementia. , 2004, , 547-559.		1
337	Clq-induced oxidative neurotoxicity: relevance for the neuropathogenesis of Alzheimer's disease. Journal of Neuroimmunology, 2003, 135, 62-71.	1.1	48
338	Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. Journal of Neuroimmunology, 2003, 138, 144-155.	1.1	83
339	Peripheral nerve induces macrophage neurotrophic activities: regulation of neuronal process outgrowth, intracellular signaling and synaptic function. Journal of Neuroimmunology, 2003, 142, 112-129.	1.1	32
340	Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: Links to HIV-1 dementia. Glia, 2003, 44, 47-56.	2.5	93
341	Inhibition of long-term potentiation by interleukin-8: Implications for human immunodeficiency virus-1-associated dementia. Journal of Neuroscience Research, 2003, 71, 600-607.	1.3	58
342	Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging. Journal of Neuroscience Research, 2003, 73, 284-295.	1.3	87

#	ARTICLE	IF	CITATIONS
343	Activation of NR1a/NR2B receptors by monocyte-derived macrophage secretory products: implications for human immunodeficiency virus type one-associated dementia. <i>Neuroscience Letters</i> , 2003, 341, 246-250.	1.0	15
344	Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. <i>Journal of Leukocyte Biology</i> , 2003, 74, 691-701.	1.5	152
345	Non-neuronal interactions in HIV-1-associated dementia. <i>Advances in Molecular and Cell Biology</i> , 2003, 31, 901-920.	0.1	1
346	Neuroprotective Activities of Sodium Valproate in a Murine Model of Human Immunodeficiency Virus-1 Encephalitis. <i>Journal of Neuroscience</i> , 2003, 23, 9162-9170.	1.7	113
347	Neuroimaging and Proteomic Tracking of Neurodegeneration in MPTP-treated Mice. <i>Annals of the New York Academy of Sciences</i> , 2003, 991, 319-321.	1.8	2
348	Generation of Cytotoxic T Cells Against Virus-Infected Human Brain Macrophages in a Murine Model of HIV-1 Encephalitis. <i>Journal of Immunology</i> , 2002, 168, 3941-3949.	0.4	69
349	Murine Models for Human Immunodeficiency Virus Type 1-Associated Dementia: The Development of New Treatment Testing Paradigms. <i>Journal of NeuroVirology</i> , 2002, 8, 49-52.	1.0	31
350	HIV-1-associated Dementia: A Metabolic Encephalopathy Perpetrated by Virus-Infected and Immune-Competent Mononuclear Phagocytes. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S43-S54.	0.9	134
351	Impaired Spatial Cognition and Synaptic Potentiation in a Murine Model of Human Immunodeficiency Virus Type 1 Encephalitis. <i>Journal of Neuroscience</i> , 2002, 22, 2096-2105.	1.7	73
352	Mononuclear phagocyte biophysiology influences brain transendothelial and tissue migration: implication for HIV-1-associated dementia. <i>Journal of Neuroimmunology</i> , 2002, 122, 40-54.	1.1	26
353	Neural Immunity: Friend or Foe?. <i>Journal of NeuroVirology</i> , 2002, 8, 474-479.	1.0	113
354	Macrophages, chemokines and neuronal injury in HIV-1-associated dementia. <i>Cellular and Molecular Biology</i> , 2002, 48, 137-50.	0.3	27
355	HIV-1-associated dementia: a basic science and clinical perspective. <i>Aids Reader</i> , 2002, 12, 358-68.	0.3	34
356	HIV-1 infected and immune competent mononuclear phagocytes induce quantitative alterations in neuronal dendritic arbor: Relevance for HIV-1-associated dementia. <i>Neurotoxicity Research</i> , 2001, 3, 443-459.	1.3	36
357	HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise. <i>Neurotoxicity Research</i> , 2001, 3, 461-484.	1.3	35
358	The regulation of alpha chemokines during HIV-1 infection and leukocyte activation: relevance for HIV-1-associated dementia. <i>Journal of Neuroimmunology</i> , 2001, 120, 112-128.	1.1	43
359	Mononuclear Phagocyte Differentiation, Activation, and Viral Infection Regulate Matrix Metalloproteinase Expression: Implications for Human Immunodeficiency Virus Type 1-Associated Dementia. <i>Journal of Virology</i> , 2001, 75, 6572-6583.	1.5	82
360	Plasma Levels of Soluble CD14 and Tumor Necrosis Factor Type II Receptor Correlate with Cognitive Dysfunction during Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 2001, 184, 699-706.	1.9	85

#	ARTICLE	IF	CITATIONS
361	Regulation of Human Immunodeficiency Virus Type 1 Infection, β -Chemokine Production, and CCR5 Expression in CD40L-Stimulated Macrophages: Immune Control of Viral Entry. <i>Journal of Virology</i> , 2001, 75, 4308-4320.	1.5	44
362	Model Systems for Assessing Cognitive Function: Implications for HIV-1 Infection and Drugs of Abuse. , 2001, 493, 7-27.		4
363	Neuronal Fractalkine Expression in HIV-1 Encephalitis: Roles for Macrophage Recruitment and Neuroprotection in the Central Nervous System. <i>Journal of Immunology</i> , 2000, 164, 1333-1339.	0.4	186
364	Cytokine-Stimulated, But Not HIV-Infected, Human Monocyte-Derived Macrophages Produce Neurotoxic Levels of α -Cysteine. <i>Journal of Immunology</i> , 2000, 164, 4265-4270.	0.4	89
365	Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity. <i>Journal of Leukocyte Biology</i> , 1999, 65, 416-427.	1.5	76
366	Unraveling the Mechanisms of Neurotoxicity in HIV Type 1-Associated Dementia: Inhibition of Neuronal Synaptic Transmission by Macrophage Secretory Products. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 57-63.	0.5	23
367	HIV-Associated Dementia: New Insights into Disease Pathogenesis and Therapeutic Interventions. <i>AIDS Patient Care and STDs</i> , 1999, 13, 153-163.	1.1	42
368	The blood-brain barrier: a defensive shield or a perpetrator of microbial invasion?. <i>Journal of NeuroVirology</i> , 1999, 5, 533-537.	1.0	3
369	Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. <i>Journal of Neuroimmunology</i> , 1999, 98, 185-200.	1.1	299
370	Microglial and Astrocyte Chemokines Regulate Monocyte Migration through the Blood-Brain Barrier in Human Immunodeficiency Virus-1 Encephalitis. <i>American Journal of Pathology</i> , 1999, 155, 1599-1611.	1.9	266
371	The cellular immunology of multiple sclerosis. <i>Journal of Leukocyte Biology</i> , 1999, 65, 444-452.	1.5	52
372	Innate and acquired immunity in neurodegenerative disorders. <i>Journal of Leukocyte Biology</i> , 1999, 65, 407-408.	1.5	17
373	Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia. <i>Journal of NeuroVirology</i> , 1999, 5, 519-528.	1.0	40
374	Lymphotropic Virions Affect Chemokine Receptor-Mediated Neural Signaling and Apoptosis: Implications for Human Immunodeficiency Virus Type 1-Associated Dementia. <i>Journal of Virology</i> , 1999, 73, 8256-8267.	1.5	125
375	Suppression of Inflammatory Neurotoxins by Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Associated Dementia. <i>Journal of Infectious Diseases</i> , 1998, 178, 1000-1007.	1.9	169
376	Human Immunodeficiency Virus Neurotropism: an Analysis of Viral Replication and Cytopathicity for Divergent Strains in Monocytes and Microglia. <i>Journal of Virology</i> , 1998, 72, 3340-3350.	1.5	94
377	Role of the β -Chemokine Receptors CCR3 and CCR5 in Human Immunodeficiency Virus Type 1 Infection of Monocytes and Microglia. <i>Journal of Virology</i> , 1998, 72, 3351-3361.	1.5	146
378	Dexamethasone Therapy Worsens the Neuropathology of Human Immunodeficiency Virus Type 1 Encephaliti in SCID Mice. <i>Journal of Infectious Diseases</i> , 1997, 175, 1368-1381.	1.9	29

#	ARTICLE	IF	CITATIONS
379	The HIV-1 associated dementia complex. <i>Current Opinion in Neurology</i> , 1997, 10, 319-326.	1.8	72
380	An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis. <i>Journal of NeuroVirology</i> , 1997, 3, 401-416.	1.0	121
381	Development of laboratory and animal model systems for HIV-1 encephalitis and its associated dementia. <i>Journal of Leukocyte Biology</i> , 1997, 62, 100-106.	1.5	54
382	The regulation of quinolinic acid in human immunodeficiency virus-infected monocytes. <i>Journal of NeuroVirology</i> , 1996, 2, 111-117.	1.0	39
383	Regulation and Characterization of the Interferon- γ Present in Patients with Advanced Human Immunodeficiency Virus Type 1 Disease. <i>Journal of Interferon and Cytokine Research</i> , 1996, 16, 127-137.	0.5	14
384	Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. <i>Trends in Immunology</i> , 1995, 16, 441-448.	7.5	110
385	The development of animal model systems for HIV-1 encephalitis and its associated dementia. <i>Journal of NeuroVirology</i> , 1995, 1, 229-243.	1.0	38
386	Utility of cerebral proton magnetic resonance spectroscopy in differential diagnosis of HIV-related dementia. <i>Journal of NeuroVirology</i> , 1995, 1, 268-274.	1.0	11
387	Dementia Associated with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1995, 332, 934-940.	13.9	476
388	Prospective Utility of Cerebral Proton Magnetic Resonance Spectroscopy in Monitoring HIV Infection and Its Associated Neurological Impairment. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 977-982.	0.5	60
389	An experimental model system for HIV-1-induced brain injury. <i>Advances in Neuroimmunology</i> , 1994, 4, 189-193.	1.8	59
390	The neuropathogenesis of HIV-1 infection. <i>Journal of Leukocyte Biology</i> , 1994, 56, 389-398.	1.5	247
391	Cellular and viral determinants that regulate HIV-1 infection in macrophages. <i>Journal of Leukocyte Biology</i> , 1994, 56, 278-288.	1.5	44
392	Human immunodeficiency virus type 1 infection of the nervous system: Pathogenetic mechanisms. <i>Annals of Neurology</i> , 1993, 33, 429-436.	2.8	377
393	No Direct Neuronotoxicity by HIV-1 Virions or Culture Fluids from HIV-1-Infected T Cells or Monocytes. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 495-503.	0.5	49
394	Interferons in the Persistence, Pathogenesis, and Treatment of HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 199-207.	0.5	121
395	Regulation of Cytokine and Viral Gene Expression in Monocytes Infected with the Human Immunodeficiency Virus. <i>Pathobiology</i> , 1991, 59, 209-213.	1.9	9
396	HIV Replication and Persistence in Human Gastrointestinal Cells Cultured In Vitro. <i>Journal of Leukocyte Biology</i> , 1991, 49, 499-504.	1.5	24

#	ARTICLE	IF	CITATIONS
397	Inhibition of human immunodeficiency virus infection in monocytes by monoclonal antibodies against leukocyte adhesion molecules. <i>Immunology Letters</i> , 1991, 30, 219-227.	1.1	42
398	Macrophages and the human immunodeficiency virus. <i>Trends in Immunology</i> , 1990, 11, 217-223.	7.5	173
399	Restriction of HIV Replication in Infected T Cells and Monocytes by Interferon- β . <i>AIDS Research and Human Retroviruses</i> , 1990, 6, 1045-1049.	0.5	63
400	Macrophages as Susceptible Targets for HIV Infection, Persistent Viral Reservoirs in Tissue, and Key Immunoregulatory Cells that Control Levels of Virus Replication and Extent of Disease. <i>AIDS Research and Human Retroviruses</i> , 1990, 6, 967-971.	0.5	112
401	Infection of Human Gastrointestinal Cells by HIV-1. <i>AIDS Research and Human Retroviruses</i> , 1990, 6, 1409-1415.	0.5	58
402	Role of Mononuclear Phagocytes in the Pathogenesis of Human Immunodeficiency Virus Infection. <i>Annual Review of Immunology</i> , 1990, 8, 169-194.	9.5	279
403	Development of an in Vitro Human Monocyte-Derived Macrophage-Based System for Drug Screening against HIV-1. <i>Annals of the New York Academy of Sciences</i> , 1990, 616, 597-598.	1.8	0
404	The Human Immunodeficiency Virus Long Terminal Repeat Is Preferentially Expressed in Langerhans Cells in Transgenic Mice. <i>AIDS Research and Human Retroviruses</i> , 1989, 5, 421-430.	0.5	69
405	Immunopathogenesis of human immunodeficiency virus infection in the central nervous system. <i>Annals of Neurology</i> , 1988, 23, S78-S81.	2.8	34
406	Effects of colony stimulating factors on the interaction of monocytes and the human immunodeficiency virus. <i>Immunology Letters</i> , 1988, 19, 193-198.	1.1	25
407	Molecular pathogenesis of human immunodeficiency virus infection. <i>Gene Analysis Techniques</i> , 1988, 5, 41-53.	1.1	4
408	A double labeling technique for performing immunocytochemistry and in situ hybridization in virus infected cell cultures and tissues. <i>Journal of Virological Methods</i> , 1985, 11, 93-103.	1.0	77
409	Selection of a fixative for identifying T cell subsets, B cells, and macrophages in paraffin-embedded mouse spleen. <i>Journal of Immunological Methods</i> , 1983, 65, 137-145.	0.6	90
410	Chemokines and the Neuropathogenesis of HIV-1 Infection. , 0, , 151-171.		1